Quantitative analysis of amyloid- peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry | Zendy

Valentina Gelfanova | Zendy; Richard E. Higgs | Zendy; Ralph A. Dean | Zendy; David M. Holtzman | Zendy; Martin R. Farlow | Zendy; Eric Siemers | Zendy; Alvin Boodhoo | Zendy; Y.-W. Qian | Zendy; X. He | Zendy; Z. Jin | Zendy; Debra Fisher | Zendy; Kay L. Cox | Zendy; John E. Hale | Zendy

Open Access

Quantitative analysis of amyloid- peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry

Author(s) -

Valentina Gelfanova,

Richard E. Higgs,

Ralph A. Dean,

David M. Holtzman,

Martin R. Farlow,

Eric Siemers,

Alvin Boodhoo,

Y.-W. Qian,

X. He,

Z. Jin,

Debra Fisher,

Kay L. Cox,

John E. Hale

Publication year - 2007

Publication title -

briefings in functional genomics and proteomics

Language(s) - English

Resource type - Journals

eISSN - 1477-4062

pISSN - 1473-9550

DOI - 10.1093/bfgp/elm010

Subject(s) - cerebrospinal fluid , immunoprecipitation , mass spectrometry , chemistry , matrix assisted laser desorption/ionization , coefficient of variation , peptide , chromatography , alzheimer's disease , gene isoform , microbiology and biotechnology , pathology , biochemistry , medicine , biology , desorption , disease , organic chemistry , adsorption , gene

Immunoprecipitation (IP) combined with matrix-assisted laser desorption ionization (MALDI) time of flight (Tof) mass spectrometry has been used to develop quantitative assays for amyloid-beta (Abeta) peptides in cerebrospinal fluid (CSF). Inclusion of (15)N labelled standard peptides allows for absolute quantification of multiple Abeta isoforms in individual samples. Characterization of variability associated with all steps of the assay indicated that the IP step is the single largest contributor to overall variability. Optimization of the assay resulted in overall coefficient of variation <or=8% with high agreement to an Abeta(1-40) and Abeta(1-42) ELISA assay. Application of the MALDI-Tof assay to CSF obtained from healthy volunteers and Alzheimer's disease patients indicated statistically significant 43% lower levels of Abeta(1-42) in the AD group (P = 0.0025).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research